Literature DB >> 26718489

Pulmonary Delivery of Anti-Tubercular Drugs Using Ligand Anchored pH Sensitive Liposomes for the Treatment of Pulmonary Tuberculosis.

Ankur Bhardwaj, Anne Grobler, Goutam Rath, Amit Kumar Goyal, Amit Kumar Jain, Abhinav Mehta1.   

Abstract

BACKGROUND: Mycobacterium tuberculosis (M. TB) remains the prime cause of bacterial mortality and morbidity world-wide. Therefore, effective delivery and targeting of drug to the cellular tropics is essentially required to generate significant results for tuberculosis treatment. The aim of the present study was to develop and characterize ligand anchored pH sensitive liposomes (TPSL) as dry powder inhaler for the targeted delivery of drugs in the target site i.e. lungs.
METHOD: Ligand anchored PSL (TPSL) was prepared by thin film hydration for the combined delivery of Isoniazid (INH) and Ciprofloxacin HCl (CIP HCl) using 4-aminophenyl-α-D mannopyranoside (Man) as surface functionalized ligand and characterized using different parameters.
RESULTS: It was observed that size of the ligand anchored liposomes (TPSL) was slightly more than the non-ligand anchored liposomes (PSL). Drug release was studied at different pH for 24 hrs and it was observed that liposomes exhibited slow release at alkaline pH (58-64%) as compared to macrophage pH (81-87%) where it increased dramatically due to the destabilization of pH sensitive liposome (PSL). In vitro cellular uptake study showed that much higher concentration was achieved in the alveolar macrophage using ligand anchored liposomes as compared to its counterpart. In vivo study showed that maximum drug accumulation was achieved in the lung by delivering drug using ligand anchored PSL as compared to conventional PSL.
CONCLUSION: It was concluded that ligand anchored pH sensitive liposome is one of the promising systems for the targeted drug therapy in pulmonary tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26718489     DOI: 10.2174/1567201813666151231093605

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  7 in total

1.  Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.

Authors:  Parham Sahandi Zangabad; Soroush Mirkiani; Shayan Shahsavari; Behrad Masoudi; Maryam Masroor; Hamid Hamed; Zahra Jafari; Yasamin Davatgaran Taghipour; Hura Hashemi; Mahdi Karimi; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2017-12-12       Impact factor: 7.848

2.  Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Authors:  Anirudh Gairola; Aaron Benjamin; Joshua D Weatherston; Jeffrey D Cirillo; Hung-Jen Wu
Journal:  Adv Ther (Weinh)       Date:  2022-03-09

3.  Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.

Authors:  Bader M Jarai; Zachary Stillman; Lucas Attia; Gerald E Decker; Eric D Bloch; Catherine A Fromen
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-20       Impact factor: 9.229

Review 4.  What lies beneath the airway mucosal barrier? Throwing the spotlight on antigen-presenting cell function in the lower respiratory tract.

Authors:  Saparna Pai; Visai Muruganandah; Andreas Kupz
Journal:  Clin Transl Immunology       Date:  2020-07-23

5.  Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche.

Authors:  Jaishree Garhyan; Surender Mohan; Vinoth Rajendran; Rakesh Bhatnagar
Journal:  Pathogens       Date:  2020-05-13

6.  Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery.

Authors:  Franklin Afinjuomo; Thomas G Barclay; Ankit Parikh; Rosa Chung; Yunmei Song; Gayathri Nagalingam; Jamie Triccas; Lixin Wang; Liang Liu; John D Hayball; Nikolai Petrovsky; Sanjay Garg
Journal:  Pharmaceutics       Date:  2019-10-28       Impact factor: 6.321

Review 7.  Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review.

Authors:  Aristote B Buya; Bwalya A Witika; Alain M Bapolisi; Chiluba Mwila; Grady K Mukubwa; Patrick B Memvanga; Pedzisai A Makoni; Christian I Nkanga
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.